Evidence map›Paper›PMID 37818359›Full record

ReviewFrontiers in immunology2023

Common methodological pitfalls in ICI pneumonitis risk prediction studies.

Yichen K Chen, Sarah Welsh, Ardon M Pillay, Benjamin Tannenwald, Kamen Bliznashki, Emmette Hutchison, John A D Aston, Carola-Bibiane Schönlieb, James H F Rudd, James Jones and 1 more

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Pulmonary toxicity of immune checkpoint inhibitors.Breathe (Sheffield, England) · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yichen K ChenDepartment of Applied Mathematics and Theoretical Physics, University of Cambridge, Cambridge, United Kingdom.
Sarah WelshDepartment of Surgery, Cambridge University Hospitals, Cambridge, United Kingdom.
Ardon M PillaySchool of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom.
Benjamin TannenwaldDigital Health, Oncology R&D, AstraZeneca, Gaithersburg, MD, United States.
Kamen BliznashkiDigital Health, Oncology R&D, AstraZeneca, Gaithersburg, MD, United States.
Emmette HutchisonDigital Health, Oncology R&D, AstraZeneca, Gaithersburg, MD, United States.
John A D AstonDepartment of Pure Mathematics and Mathematical Statistics, University of Cambridge, Cambridge, United Kingdom.
Carola-Bibiane SchönliebDepartment of Applied Mathematics and Theoretical Physics, University of Cambridge, Cambridge, United Kingdom.
James H F RuddDepartment of Medicine, University of Cambridge, Cambridge, United Kingdom.
James JonesDepartment of Oncology, Cambridge University Hospitals, Cambridge, United Kingdom.
Michael RobertsDepartment of Applied Mathematics and Theoretical Physics, University of Cambridge, Cambridge, United Kingdom.

Funding

British Heart FoundationCancer Research UK C9685/A25177Department of HealthWellcome TrustWellcome Trust RG98755
6 · The paper itself

Abstract

Background: Pneumonitis is one of the most common adverse events induced by the use of immune checkpoint inhibitors (ICI), accounting for a 20% of all ICI-associated deaths. Despite numerous efforts to identify risk factors and develop predictive models, there is no clinically deployed risk prediction model for patient risk stratification or for guiding subsequent monitoring. We believe this is due to systemic suboptimal approaches in study designs and methodologies in the literature. The nature and prevalence of different methodological approaches has not been thoroughly examined in prior systematic reviews. Methods: The PubMed, medRxiv and bioRxiv databases were used to identify studies that aimed at risk factor discovery and/or risk prediction model development for ICI-induced pneumonitis (ICI pneumonitis). Studies were then analysed to identify common methodological pitfalls and their contribution to the risk of bias, assessed using the QUIPS and PROBAST tools. Results: There were 51 manuscripts eligible for the review, with Japan-based studies over-represented, being nearly half (24/51) of all papers considered. Only 2/51 studies had a low risk of bias overall. Common bias-inducing practices included unclear diagnostic method or potential misdiagnosis, lack of multiple testing correction, the use of univariate analysis for selecting features for multivariable analysis, discretization of continuous variables, and inappropriate handling of missing values. Results from the risk model development studies were also likely to have been overoptimistic due to lack of holdout sets. Conclusions: Studies with low risk of bias in their methodology are lacking in the existing literature. High-quality risk factor identification and risk model development studies are urgently required by the community to give the best chance of them progressing into a clinically deployable risk prediction model. Recommendations and alternative approaches for reducing the risk of bias were also discussed to guide future studies.

Indexed as

PneumoniaHumansJapanRisk FactorsSystematic Reviews as Topicimmune checkpoint inhibitor induced pneumonitisreview of methodologyrisk of bias assessmentstatistical analysisstudy design

Identifiers

PMID37818359
PMCPMC10560723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.